Patents by Inventor Daiguo DENG

Daiguo DENG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUND AS VOLTAGE-GATED SODIUM CHANNEL INHIBITOR
    Publication number: 20260257996
    Abstract: Provided are a compound as a voltage-gated sodium channel inhibitor, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof. The compound has the structural characteristics of formula (I).
    Type: Application
    Filed: August 11, 2023
    Publication date: September 3, 2026
    Applicant: Guangzhou Fermion Technology Co., Ltd.
    Inventors: Daiguo DENG, Wenhe ZHONG, Jielian LU, Zengrong LEI
  • SUBSTITUTED PYRIDAZINE-3-CARBOXAMIDE COMPOUND SERVING AS TYK2 INHIBITOR
    Publication number: 20260258016
    Abstract: The present invention provides a pyridazine-3-carboxamide compound represented by general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof. The present invention further provides a pharmaceutical composition including the compound, a preparation method therefor and a use thereof in treating or preventing a TYK2 kinase-mediated disease.
    Type: Application
    Filed: June 6, 2023
    Publication date: September 3, 2026
    Applicant: Guangzhou Fermion Technology Co., Ltd.
    Inventors: Daiguo DENG, Wenhe ZHONG, Jielian LU, Zengrong LEI
  • PYRIDAZIN-3-CARBOXAMIDE COMPOUND AS TYK2 INHIBITOR
    Publication number: 20260256779
    Abstract: The present invention provides a pyridazine-3-carboxamide compound represented by general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof. The present invention further provides a pharmaceutical composition including the compound, a preparation method therefor and a use thereof in treating or preventing a TYK2 kinase-mediated disease.
    Type: Application
    Filed: June 6, 2023
    Publication date: September 3, 2026
    Applicant: Guangzhou Fermion Technology Co., Ltd.
    Inventors: Daiguo DENG, Wenhe ZHONG, Jielian LU, Zengrong LEI
  • Compound as voltage-gated sodium channel inhibitor
    Patent number: 12521399
    Abstract: Provided are a compound as a voltage-gated sodium channel inhibitor, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof. The compound has the structural characteristics of formula (I).
    Type: Grant
    Filed: March 14, 2025
    Date of Patent: January 13, 2026
    Assignee: Guangzhou Fermion Technology Co., Ltd.
    Inventors: Daiguo Deng, Wenhe Zhong, Jielian Lu, Zengrong Lei
  • COMPOUND AS VOLTAGE-GATED SODIUM CHANNEL INHIBITOR
    Publication number: 20250262220
    Abstract: Provided are a compound as a voltage-gated sodium channel inhibitor, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof. The compound has the structural characteristics of formula (I).
    Type: Application
    Filed: March 14, 2025
    Publication date: August 21, 2025
    Inventors: Daiguo Deng, Wenhe Zhong, Jielian Lu, Zengrong Lei
  • FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
    Publication number: 20230192683
    Abstract: The present invention relates to a fused-ring compound and a preparation method, a pharmaceutical composition, and an application thereof. The fused-ring compound has structural features of Formula (I). The fused-ring compound belongs to a class of somatostatin receptor subtype 4 (SSTR4) agonist compounds having novel structures, improved efficacy, high bioavailability, and improved solubility.
    Type: Application
    Filed: May 21, 2021
    Publication date: June 22, 2023
    Applicant: Guangzhou Fermion Technology Co., Ltd.
    Inventors: Daiguo DENG, Guanpeng QIU, Yonggang WANG, Zengrong LEI